An Update on Promising Agents against COVID-19: Secondary Metabolites and
Mechanistic Aspects

Jamshidnia, M.; Sewell, Robert David Edmund; Rafieian-Kopaei, Mahmoud

doi:10.2174/1381612828666220722124826

Cited by 6 publications

(5 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Natural products, may be selective antiviral agents [32], but their effectiveness can be limited by high cytotoxicity or low antiviral activity [33]. Further research on the anti-viral properties of phytochemicals will allow for the development of target-specific drug delivery systems.…”

Section: Phytochemicals As Antiviralsmentioning

confidence: 99%

Phytochemicals in Drug Discovery - A Confluence of Tradition and Innovation

Chihomvu,

Ganesan,

Gibbons

et al. 2024

Preprint

View full text Add to dashboard Cite

Phytochemicals have a long and successful history in drug discovery. With recent advancements in analytical techniques and methodologies, discovering bioactive leads from natural compounds has become easier. Computational techniques like molecular docking, QSAR modelling and machine learning, and network pharmacology are among the most promising new tools that allow researchers to make predictions concerning natural products' potential targets, thereby guiding experimental validation efforts. Additionally, approaches like LC-MS or LC-NMR speed up compound identification by streamlining analytical processes. Integrating structural and computational biology aids in lead identification, thus providing invaluable information to understand how phytochemicals interact with potential targets in the body. Emerging computational approach is machine learning involving QSAR modelling and deep neural networks that interrelate phytochemical properties with diverse physiological activities such as antimicrobial or anticancer effects.

show abstract

Section: Phytochemicals As Antiviralsmentioning

confidence: 99%

Phytochemicals in Drug Discovery - A Confluence of Tradition and Innovation

Chihomvu,

Ganesan,

Gibbons

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…In silico analysis has revealed that PSMs could be one of the most valuable drug targets against SARS-CoV-2 [ 37 ]. There are many recent review papers published on the PSMs against SARS-CoV-2 [ 36 , 37 , 125 , 129 , 131 , 132 , 133 , 134 , 135 , 136 ]. A comprehensive list of medicinal plants and their active compounds with inhibitory activity against SARS-CoV-2 can be seen in the recent reviews [ 37 , 131 , 132 , 137 ].…”

Section: Medicinal Plant-produced Metabolites (Small Molecules) Again...mentioning

confidence: 99%

Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19

England

TrejoMartinez

PerezSanchez

et al. 2023

Life

View full text Add to dashboard Cite

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a profound impact on the world’s health and economy. Although the end of the pandemic may come in 2023, it is generally believed that the virus will not be completely eradicated. Most likely, the disease will become an endemicity. The rapid development of vaccines of different types (mRNA, subunit protein, inactivated virus, etc.) and some other antiviral drugs (Remdesivir, Olumiant, Paxlovid, etc.) has provided effectiveness in reducing COVID-19’s impact worldwide. However, the circulating SARS-CoV-2 virus has been constantly mutating with the emergence of multiple variants, which makes control of COVID-19 difficult. There is still a pressing need for developing more effective antiviral drugs to fight against the disease. Plants have provided a promising production platform for both bioactive chemical compounds (small molecules) and recombinant therapeutics (big molecules). Plants naturally produce a diverse range of bioactive compounds as secondary metabolites, such as alkaloids, terpenoids/terpenes and polyphenols, which are a rich source of countless antiviral compounds. Plants can also be genetically engineered to produce valuable recombinant therapeutics. This molecular farming in plants has an unprecedented opportunity for developing vaccines, antibodies, and other biologics for pandemic diseases because of its potential advantages, such as low cost, safety, and high production volume. This review summarizes the latest advancements in plant-derived drugs used to combat COVID-19 and discusses the prospects and challenges of the plant-based production platform for antiviral agents.

show abstract

“…Many of them predominantly centre on molecular docking studies, focusing on the theoretical interactions between plant‐derived compounds and the virus at a molecular level (Jamshidnia et al, 2022; Malekmohammad & Rafieian‐Kopaei, 2021). While this offers valuable insights into potential mechanisms of action, it might not fully capture the clinical implications or real‐world therapeutic efficacy.…”

Section: Introductionmentioning

confidence: 99%

“…Aspects of this field have previously been reviewed (Ahmad et al, 2021; Hu et al, 2021; Jamshidnia et al, 2022; Malekmohammad & Rafieian‐Kopaei, 2021; Raimi et al, 2022), and this current review seeks to provide a comprehensive update on the use of phytochemicals and traditional plant‐based remedies as potential new leads for drug development targeting SAR‐CoV‐2. Beyond presenting an inventory of plants and potential benefits, it delves into the intricacies and challenges accompanying these treatments, such as bioavailability issues and potential herb–drug interactions.…”

Section: Introductionmentioning

confidence: 99%

Plant‐derived compounds as potential leads for new drug development targeting COVID‐19

Liu,

Kapralov,

Ashton

2024

Phytotherapy Research

View full text Add to dashboard Cite

COVID‐19, which was first identified in 2019 in Wuhan, China, is a respiratory illness caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Although some patients infected with COVID‐19 can remain asymptomatic, most experience a range of symptoms that can be mild to severe. Common symptoms include fever, cough, shortness of breath, fatigue, loss of taste or smell and muscle aches. In severe cases, complications can arise including pneumonia, acute respiratory distress syndrome, organ failure and even death, particularly in older adults or individuals with underlying health conditions. Treatments for COVID‐19 include remdesivir, which has been authorised for emergency use in some countries, and dexamethasone, a corticosteroid used to reduce inflammation in severe cases. Biological drugs including monoclonal antibodies, such as casirivimab and imdevimab, have also been authorised for emergency use in certain situations. While these treatments have improved the outcome for many patients, there is still an urgent need for new treatments. Medicinal plants have long served as a valuable source of new drug leads and may serve as a valuable resource in the development of COVID‐19 treatments due to their broad‐spectrum antiviral activity. To date, various medicinal plant extracts have been studied for their cellular and molecular interactions, with some demonstrating anti‐SARS‐CoV‐2 activity in vitro. This review explores the evaluation and potential therapeutic applications of these plants against SARS‐CoV‐2. This review summarises the latest evidence on the activity of different plant extracts and their isolated bioactive compounds against SARS‐CoV‐2, with a focus on the application of plant‐derived compounds in animal models and in human studies.

show abstract

An Update on Promising Agents against COVID-19: Secondary Metabolites and Mechanistic Aspects

Cited by 6 publications

References 108 publications

Phytochemicals in Drug Discovery - A Confluence of Tradition and Innovation

Phytochemicals in Drug Discovery - A Confluence of Tradition and Innovation

Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19

Plant‐derived compounds as potential leads for new drug development targeting COVID‐19

Contact Info

Product

Resources

About